RE: Passing along info...I found it interesting to note before Lux started Phase 3 back in Feb 21, 2007, that their CEO Ulrich Grau said:
“Our aim is to bring steroids down below 7.5 mg per day, and if possible, get them tapered to zero,” Lux
President and CEO Ulrich Grau told BioWorld Today, noting that steroid-sparing drugs such as methotrexate
sometimes are worked into patients’ treatment regimens despite their own deleterious side effects. “It’s a bit
of dance on a tight rope, so to speak,” he added, and removing either steroids or steroid-sparing drugs
causes the disease to flare and leads to eventual blindness. So there is a medical need for “something
suitable for long-term treatment in these patients,” Grau said.
https://www.luxbio.com/BWT%20022107%20-%20Lux%20Starts%20Phase%20III%20Studies%20Isotechnika%20Raises%20345M.pdf
Two years + later they have confirmed less than this in the trials and mentioned that typical chronic dosage for patients is around 25mg when the recommended dosage is only 10mg as per Lux news release.
Two years + later they have confirmed less than this in the trials and mentioned that typical chronic dosage for patients is around 25mg when the recommended dosage is only 10mg as per Lux news release.
"The tapering of systemic corticosteroids to 5 mg or less per day, as implemented successfully in the LUMINATE studies, provides for additional safety from steroid morbidities," Dr. Rosenbaum commented.
"We are pleased with the demonstrated clinical effect of LX211 (Luveniq(TM)) in uveitis, coupled with what appears to be an acceptable side effect profile while reducing the need for systemic corticosteroid to half of the current guideline recommendation," commented Ulrich Grau, Ph.D., Lux Biosciences' President and Chief Executive Officer.
IMO, certainly sounds like their is an unmet medical need with this indication.